Source: BEFREE

Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 55
Gene Symbol: ACP3
ACP3
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 Biomarker BEFREE These data suggest that a significant amount of PAP and its synthesizing polysomes was reduced in prostate cancer as a result of PAP gene suppression. 7296542

1981

Entrez Id: 133418
Gene Symbol: EMB
EMB
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.020 Biomarker BEFREE A human prostate carcinoma line that had not been grown in the athymic mice was found to have no gp70, but was shown to be able to synthesize gp70 after a single passage in the athymic mice. 6307513

1983

Entrez Id: 3458
Gene Symbol: IFNG
IFNG
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 Biomarker BEFREE Interferon-gamma (IFN-gamma) production by peripheral blood leukocytes from bladder cancer patients was compared with that of patients with prostate cancer and benign prostatic hyperplasia, nontumor-bearing patients with bacterial infections, and normal controls. 6426791

1984

Entrez Id: 2638
Gene Symbol: GC
GC
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.070 GeneticVariation BEFREE The distribution of phenotypes and gene frequencies of the third component of complement (C3), group-specific component (Gc), haptoglobin (Hp) and transferrin (Tf) were studied in 115 patients with carcinoma of the prostate. 6596192

1984

Entrez Id: 3240
Gene Symbol: HP
HP
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.050 GeneticVariation BEFREE The distribution of phenotypes and gene frequencies of the third component of complement (C3), group-specific component (Gc), haptoglobin (Hp) and transferrin (Tf) were studied in 115 patients with carcinoma of the prostate. 6596192

1984

Entrez Id: 83733
Gene Symbol: SLC25A18
SLC25A18
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.010 Biomarker BEFREE On the contrary, a statistically significant association was found between carcinoma of prostate and C3F and Gc2 genes. 6596192

1984

Entrez Id: 171558
Gene Symbol: PTCRA
PTCRA
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.010 Biomarker BEFREE An inhibitor of plasma thromboplastin antecedent (PTA, factor XI), measured in coagulant and radioimmunoassays, was detected in a 60-year-old man with carcinoma of the prostate who had no evidence of a bleeding tendency. 3486671

1986

Entrez Id: 2160
Gene Symbol: F11
F11
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.010 Biomarker BEFREE An inhibitor of plasma thromboplastin antecedent (PTA, factor XI), measured in coagulant and radioimmunoassays, was detected in a 60-year-old man with carcinoma of the prostate who had no evidence of a bleeding tendency. 3486671

1986

Entrez Id: 2247
Gene Symbol: FGF2
FGF2
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 AlteredExpression BEFREE Using Northern blot analysis we now show that the messenger RNA for bFGF but not aFGF is expressed in benign prostatic hyperplastic (BPH) tissue as well as in carcinoma of the prostate (CAP). 2463616

1988

Entrez Id: 1950
Gene Symbol: EGF
EGF
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 Biomarker BEFREE Prostate carcinoma contained higher concentrations of EGF receptors based on DNA than did BPH, although it is accepted that BPH may not be the appropriate comparison for carcinoma. 2468269

1988

Entrez Id: 3479
Gene Symbol: IGF1
IGF1
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 Biomarker BEFREE Specimens of benign prostatic hypertrophy (BPH) and prostate carcinoma and prostate cells in culture were assessed for their capacity to bind androgens, radioiodinated EGF, and IGF-I, and to express certain cellular protooncogenes. 2468269

1988

Entrez Id: 2246
Gene Symbol: FGF1
FGF1
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.040 AlteredExpression BEFREE Using Northern blot analysis we now show that the messenger RNA for bFGF but not aFGF is expressed in benign prostatic hyperplastic (BPH) tissue as well as in carcinoma of the prostate (CAP). 2463616

1988

Entrez Id: 5340
Gene Symbol: PLG
PLG
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.090 Biomarker BEFREE Plasminogen activators in human prostate cancer cell lines and tumors: correlation with the aggressive phenotype. 2659823

1989

Entrez Id: 367
Gene Symbol: AR
AR
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 Biomarker BEFREE We have explored the basis for this heterogeneity by examining the levels of androgen receptor expression in a prostate carcinoma cell line (LNCaP) that expresses the androgen receptor and two prostate carcinoma cell lines that do not contain detectable androgen receptor. 2386943

1990

Entrez Id: 354
Gene Symbol: KLK3
KLK3
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker BEFREE Both PSA and DNA ploidy analysis by flow cytometry appear to be valuable indicators in the evaluation of patients with prostatic carcinoma. 1710533

1991

Entrez Id: 6462
Gene Symbol: SHBG
SHBG
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 Biomarker BEFREE Effects of sex hormone binding globulin (SHBG) on human prostatic carcinoma. 1958578

1991

Entrez Id: 7157
Gene Symbol: TP53
TP53
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 AlteredExpression BEFREE Immunocytochemical data indicate that prostate carcinoma cells expressing the transfected wild-type p53 gene are growth arrested because they exhibit a reduced level of thymidine incorporation into DNA. 1873816

1991

Entrez Id: 5327
Gene Symbol: PLAT
PLAT
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.060 GeneticVariation BEFREE Our data suggest that tumor suppressor genes involved in the oncogenesis of prostatic carcinoma may be localized between 8 pter and the PLAT locus and that additional/alternative tumor suppressor genes may be localized on chromosome 10 and on the long arm of chromosome 16 distal to the D16S4 locus. 1868037

1991

Entrez Id: 3265
Gene Symbol: HRAS
HRAS
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.020 GeneticVariation BEFREE In this paper, we report a comprehensive screening of 19 CaPs and 3 CaP cell lines for activating point mutations in the sequences of the 12th and 61st codons of c-Ha-ras-1 and the c-Ki-ras-2 genes, as well as the 12th, 13th, and 61st codons of the c-N-ras gene. 1998954

1991

Entrez Id: 354
Gene Symbol: KLK3
KLK3
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker BEFREE Prostate-specific antigen (PSA) has emerged as the most useful marker for management of patients with prostate cancer. 1379363

1992

Entrez Id: 354
Gene Symbol: KLK3
KLK3
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.200 Biomarker BEFREE Quantitative estimation of tissue prostate specific antigen, deoxyribonucleic acid ploidy and cytological grade in fine needle aspiration biopsies for prognosis of hormonally treated prostatic carcinoma. 1380992

1992

Entrez Id: 55
Gene Symbol: ACP3
ACP3
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 Biomarker BEFREE To establish the relationship of cellular PAcP activity with cell growth rate, we transfected a complementary DNA encoding the full length PAcP protein into another human prostate carcinoma line, PC-3, that lacks endogenous PAcP. 1380886

1992

Entrez Id: 7157
Gene Symbol: TP53
TP53
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 Biomarker BEFREE These observations in clinical specimens of primary and metastatic sites provide evidence for the association of the p53 gene in the progression of human prostate carcinoma. 1347085

1992

Entrez Id: 2247
Gene Symbol: FGF2
FGF2
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 Biomarker BEFREE We observed that these three prostate cancer cell lines, which differed in their dependence on androgens for growth in vitro and in their in vivo behavior in nude mice, could be distinguished as follows: (a) androgen-sensitive LNCaP cells, which do not metastasize in nude mice, did not produce measurable amounts of bFGF, expressed small but measurable amounts of FGF receptor mRNA, and did respond to exogeneous bFGF; (b) androgen-insensitive, moderately metastatic DU 145 cells did produce measurable amounts of biologically active bFGF, expressed large amounts of FGF receptor mRNA, and responded to exogeneous bFGF and the heparin-binding fractions from DU 145 cell extracts; (c) androgen-insensitive and highly metastatic PC3 cells also produced measurable amounts of bFGF but did not demonstrate a growth response to either the heparin-binding fractions from PC3 cell extracts or exogenous bFGF, even though large amounts of FGF receptor mRNA were expressed in PC 3 cells. 1732045

1992

Entrez Id: 5111
Gene Symbol: PCNA
PCNA
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 Biomarker BEFREE Proliferative activity determined by DNA flow cytometry and proliferating cell nuclear antigen (PCNA) immunohistochemistry as a prognostic factor in prostatic carcinoma. 1360498

1992